Research institution
Peking University People's Hospital Clinical Trials
Studies where Peking University People's Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 194Acute Lymphoblastic Leukemia, Hematopoietic Stem Cell Transplantation
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
This is an multicenter, non-inferiority randomized controlled trial. Adult patients (14-65 years) with acute lymphoblastic leukemia in second complete remission (CR2) scheduled for allogeneic hematopoietic stem-cell…
- Trial name
- NCT07919470
- Testing
- Chemotherapy-based Conditioning Regimen, TBI-based conditioning
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University People's Hospital
Hemophagocytic Lymphohistiocytosis (HLH)
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation.
- Trial name
- HSCT-HLH (NCT07905066)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Peking University People's Hospital
Lung Neoplasms, Neoadjuvant Therapy
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy.
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07894458
- Testing
- Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Non-Small Cell Lung Cancer (NSCLC)
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Neoadjuvant immunotherapy combined with platinum-based doublet chemotherapy has been established as the standard of care for driver-gene-negative (EGFR/ALK wild-type) stage II-IIIB non-small cell lung cancer (NSCLC), yielding…
- Trial name
- NCT07885709
- Testing
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Prospective ctDNA Testing in Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) are aggressive lymphomas commonly treated with first-line immunochemotherapy. Some patients experience disease progression or relapse despite treatment.
- Trial name
- NCT07878351
- Testing
- Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such as R-CHOP, Pola-R-CHP, or DA-EPOCH-R.
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer
Effect of Weight Management on AMPK Activation in the Adjunctive Treatment of Endometrial Cancer
This study will randomly assign overweight or obese patients with endometrial cancer undergoing fertility-sparing treatment to two groups.
- Trial name
- NCT07879365
- Testing
- DEAR-Based Comprehensive Weight Management, Balanced Diet and Self-Directed Exercise
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University People's Hospital
Non-Small Cell Lung Cancer
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
Despite complete (R0) resection, patients with EGFR-mutant stage IIA-IIIB non-small cell lung cancer (NSCLC) still face a substantial risk of postoperative recurrence.
- Trial name
- NCT07873086
- Testing
- Aumolertinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Adult
NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study
This prospective, single-center, randomized controlled clinical trial aims to evaluate whether N-acetyl-L-cysteine (NAC) can promote hematopoietic recovery after chemotherapy in patients with acute myeloid leukemia (AML), and to…
- Trial name
- 2026-07-06 (NCT07869342)
- Testing
- N-acetyl-L-cysteine (NAC)
- Volunteers
- 180 people
- Sponsor
- Peking University People's Hospital
Pilonidal Sinus Disease
VAAPS Combined With Loose Seton Drainage for Postoperative Self-Care: A Prospective Single-Arm Cohort Study
Pilonidal sinus is a chronic infection of the sacrococcygeal skin that mainly affects young adults. Traditional surgery leaves large wounds requiring weeks of daily dressing changes away from home.
- Trial name
- PKUPH-PS01 (NCT07855107)
- Testing
- VAAPS with Loose Seton Drainage
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Early Gastric Cancer
LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
Early gastric cancer (EGC) is traditionally treated with either endoscopic resection or standard laparoscopic gastrectomy with formal lymph node dissection.
- Trial name
- LENS (NCT07857668)
- Testing
- Procedure: LECS combined with LSNNS
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Completed, with results posted
All –Systemic Lupus Erythematosus
Low-dose IL-2( Interleukin-2) Treatment in SLE
This clinical study will test the efficacy and safety of low dose IL-2 treatment in Systemic lupus erythematosus.
- Trial name
- NCT02084238
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Rheumatoid Arthritis
Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by symmetric poly-arthritis usually involving the small joints of the hands and feet.
- Trial name
- NCT02467504
- Testing
- hrIL-2 active, MTX, Folic Acid
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University People's Hospital